Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
Health Technol Assess
.
2018 Feb;21(2):219-220.
doi: 10.3310/hta21020-c201802.
Authors
Rhona Johnston
1
,
Olalekan Uthman
2
,
Ewen Cummins
1
,
Christine Clar
3
,
Pamela Royle
2
,
Jill Colquitt
4
,
Bee Kang Tan
2
,
Andrew Clegg
5
,
Saran Shantikumar
2
,
Rachel Court
2
,
J Paul O'Hare
2
,
David McGrane
6
,
Tim Holt
7
,
Norman Waugh
2
Affiliations
1
McMDC, Harrogate, UK.
2
Warwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UK.
3
Berlin, Germany.
4
Effective Evidence, Waterlooville, UK.
5
University of Central Lancashire, Preston, UK.
6
Queen Elizabeth University Hospital, Glasgow, UK.
7
University of Oxford, Oxford, UK.
PMID:
29508697
DOI:
10.3310/hta21020-c201802
No abstract available
Publication types
Published Erratum